Written by : Dr. Aishwarya Sarthe
December 6, 2024
The entire funding raised in November 2024 came from seed-stage and early-stage rounds, which accounted for 93.7% and 6.3% of the total investments, respectively.
Funding in the pharma and healthcare space took a dramatic plunge in November 2024, with a 94.52% drop, falling from $73.4 million in October to just $4.02 million.
This marks an even more severe 95.87% decline compared to November 2023, when $97.3 million was raised.
The entire funding raised in November 2024 came from seed-stage and early-stage rounds, which accounted for 93.7% and 6.3% of the total investments, respectively.
This indicates a significant shift towards smaller, early-stage investments, as larger funding rounds were notably absent during the month.
Assure and India IVF Clinic emerged as the biggest beneficiaries of funding in November 2024. Assure raised $1.8 million, while India IVF Clinic secured $1.3 million, making up a substantial portion of the total funding for the month.
Keiretsu Forum, Venture Catalysts, and Tomorrow Capital were the most active investors during the period. These investors focused primarily on early-stage funding, despite the overall downturn in the healthcare investment market.
The healthcare funding landscape faced a severe downturn in November 2024, with the total raised funding plummeting by over 90% from the previous month and year. Seed-stage investments dominated the funding activity, reflecting a cautious investor sentiment and a preference for smaller, less risky investments.